GMDA News and Press, Gamida Cell Ltd. From 11/05/19

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Wednesday, November 13, 2019, at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on...

MKM partners initiates coverage on seven pot stocks: Curaleaf Holdings ( OTCPK:CURLF ): Sell, Aurora Cannabis (NYSE: ACB ): Sell ( -1% ), Canopy Growth (NYSE: CGC ): Neutral (up a fraction), Tilray (NASDAQ: TLRY ): Neutral (up a fraction), Cronos Group (NASDAQ: CRON ): Neutral ( +1% ), ...

– Multi-Year Observational Study Designed to Evaluate Outcomes of Patients with Hematologic Malignancies Who Undergo Allogeneic Bone Marrow Transplantation – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and the CIBMTR ® (Cente...

Gamida Cell Ltd. (GMDA) Q2 2019 Earnings Conference Call August 06, 2019, 08:30 ET Company Participants Julian Adams - CEO Ronit Simantov - Chief Medical Officer Shai Lankry - CFO Thomas Klima - Chief Commercial Officer Conference Call Participants Gregory Renza - RBC Cap...

– Successfully completed follow-on public offering raising approximately $40 million in gross proceeds – – Patient enrollment in Phase 3 study of omidubicel expected to be completed by year-end 2019; Topline data expected in first half of 2020 – ...

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Tuesday, August 6, 2019, at 8:30 a.m. ET to review its second quarter 2019 financial results and provide an update on the...

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the underwriters of its recently closed underwritten public offering of 7,000,000 ordinary shares have exercised in full their option to purchase an additional 1,050,000 ordinary shares...

Gamida Cell (NASDAQ: GMDA ) prices its public offering of 7M ordinary shares at $5/share for aggregate gross proceeds of $35M. More news on: Gamida Cell Ltd., Healthcare stocks news, Read more ...

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35 million, before deducting underw...

Gainers:  Pyxus International (NYSE: PYX ) +28% . Allergan (NYSE: AGN ) +26% . ENDRA Life Sciences (NASDAQ: NDRA ) +23% . Pier 1 Imports (NYSE: PIR ) +18% . Rafael Holdings (NYSEMKT: RFL ) +16% . Riot Blockchain (NASDAQ: RIOT ) +15% . Vislink Technologies (NASDAQ: VISL ) +15% ....